[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483954":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":52,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A2 donor transplant to O recipient","EXPERIMENTAL",null,[13],"Procedure: Blood group A2 donor to blood group O recipient lung transplant surgery",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","Blood group A2 donor to blood group O recipient lung transplant surgery","Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant",[9],[21],{"name":22,"affiliation":5,"role":23},"Shaf Keshavjee, MD MSc FRCSC FACS","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Sharaniyaa Balachandran","CONTACT","416-340-4800","6549","sharaniyaa.balachandran@uhn.ca",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Toronto General Hospital, University Health Network","RECRUITING","Toronto","Ontario","M5G 2C4","Canada",{"type":40,"coordinates":41},"Point",[42,43],-79.39864,43.70643,{"lat":43,"lon":42},[46,47,49],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":48,"role":23,"phone":11,"phoneExt":11,"email":11},"Shaf Keshavjee, MD MSc",{"name":50,"role":51,"phone":11,"phoneExt":11,"email":11},"Meghan Aversa, MD MSc","SUB_INVESTIGATOR",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100483954",false,"NCT05581745","A2 to O Lung Transplants","Blood Group A2 Donor to Blood Group O Recipient Lung Transplantation","Inclusion Criteria:\n\n* first lung transplant\n* blood group O recipient\n* low pre-operative anti-A antibody titers\n* consent to study participation\n\nExclusion Criteria:\n\n* re-transplant\n* multiorgan transplant\n* positive virtual crossmatch at time of transplant","ALL","18 Years",{"count":63,"type":64},10,"ESTIMATED","INTERVENTIONAL",[67],"NA","Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.",[70,71],"Lung Transplant","ABO Incompatibility","2025-02-03",{"date":74,"type":75},"2025-02-06","ACTUAL",{"date":77,"type":75},"2022-07-14",{"date":79,"type":64},"2033-12-31",{"name":5,"class":6},1]